Fotantinib/Fotantinib Dosage Guide

In overseas instructions and medication guidelines, the usage and dosage design of Fostamatinib for the treatment of chronic immune thrombocytopenia (ITP) emphasizes the principles of gradual and individualized adjustment. The drug is administered orally. The starting dose is usually 100 mg twice a day. It can be taken with food or on an empty stomach. This method of administration improves patient compliance to a certain extent. The main purpose of dose setting in the initial stage is to observe the patient's initial response and tolerance to the drug while ensuring safety.

After about one month of continuous use, if the platelet level still does not meet the clinical needs for reducing the risk of bleeding, overseas guidelines recommend that the dose be adjusted to 150 mg twice a day after a doctor's evaluation. It should be noted that dose increase is not an automatic step, but is based on efficacy evaluation and adverse reaction monitoring. If the platelet count does not reach a level sufficient to avoid clinically significant bleeding after approximately 12 weeks of treatment, the treatment plan usually needs to be re-evaluated and fostatinib discontinued if necessary.

Overall, fotantinib dosage management emphasizes the concept of "using the lowest effective dose", that is, trying to avoid unnecessary dose burden on the premise of achieving and maintaining safe platelet levels. This idea is relatively common in overseas chronic disease management, and also reflects the consideration of long-term medication safety. For patients, it is more important to strictly follow the dosage adjustment plan prescribed by the doctor than to simply pursue a rapid plateau increase. This is also the key to the stable value of fostatinib in the treatment of chronic ITP.

Reference materials:https://go.drugbank.com/drugs/DB12010